George Clinical – CRO China

George Clinical in China

Tweet about this on TwitterShare on FacebookShare on LinkedIn

China is George Clinical’s largest hub outside the head office of Sydney, offering full CRO services and a site network that spans the country.

With its immense potential for patient recruitment and a rapidly growing pharmaceutical market, China, currently the third largest in the world, is an obvious choice for many when entering the Asian market.

The Chinese healthcare delivery system consists of public hospitals and community healthcare centers, with an increasing private care system. Only GCP accredited sites are eligible for running commercial Phase I, II and III studies, and this accreditation can only be achieved by public hospitals in China. The accreditation is issued by the CFDA and NHPFC based upon a site inspection. Accreditation is renewed every 3 years, with a quality review performed by the PFDA every year.

George Clinical has an extensive network of over 260 trial centers in 50 cities for Phase II-IV trials, and a wider network that includes community health centers in semi-urban and rural areas for Phase IV trials.

What are the benefits of conducting clinical trials in China?

  • China has access to a large patient pool
  • Rapidly developing medical infrastructure in urban centres and centres of excellence for many common diseases such as hypertension, diabetes and renal disease
  • Low operational costs

What are the prevalent diseases in China?

  1. Stroke
  2. Ischaemic Heart Disease
  3. Chronic obstructive pulmonary disease
  4. Cancer
  5. Road injury
  6. Hypertension
  7. Diabetes mellitus
  8. Lower respiratory infections

George Clinical China News

乔治健康研究所所长Craig Anderson教授受聘成都医学院客座教授

4月19日,乔治健康研究所所长Craig Anderson教授前往成都医学院进行访问交流并被授予客座教授。

Professor Craig Anderson from TGI has been honored as a Guest Professor of Chengdu Medical College

On 19 April 2017, Professor Craig Anderson, Executive Director of the George Institute China received a new appointment as a guest professor at Chengdu Medical College (CMC).

PLoS ONE:非工作时间就诊的ST段抬高型心肌梗死患者死亡率较高

2017年4月7日, 国际知名综合性学术期刊PLoS ONE在线发表了北京大学医学部乔治健康研究所武阳丰教授所主持的中国急性冠脉综合症临床路径研究三期(CPACS-3)课题最新研究成果 – 周末和夜间就诊的ST段抬高型心肌梗死患者(STEMI)死亡率较高(Factors attributed to the higher in-hospital mortality of ST elevation myocardial infarction patients admitted during off-hour in comparison wi...

PLoS ONE:Higher in-hospital mortality of STEMI patients admitted during off-hour

Clinical Pathways for Acute Coronary Syndromes in China (CPACS-3) research from The George Institute China has revealed factors attributed to the higher in-hospital mortality of ST elevation myocardial infarction (STEMI) patients admitted during off-hour in comparison wi...


乔治健康研究所入围2017年“澳大利亚商会中澳商业大奖(ACBA)”之 “最佳可持续发展及企业社会责任奖”。

The George Institute, China selected as finalist in the 2017 AustCham Westpac Australia-China Business Awards

The George Institute, China has been selected as a finalist in the AustCham Westpac Australia-China Business Awards (ACBA) of 2017, in the Business Excellence for Sustainability, Diversity and Social Responsibility category.


George Clinical Address:
Level 18, Tower B, Horizon Tower
Haidian District
Beijing, 100088
P.R. China

2223, 22/F Tomson Commercial Building,
710 Dongfang Road, Pudong District
Shanghai, 200122
P.R. China


Number of Personnel: 50
In-country Services:

Project Management, Clinical Operations, Data Management, Medical and Safety Services, Clinical Compliance, Regulatory Services, Statistics, Health Economics

Clinical Operations

Clinical Operations

Project Management, Clinical Operations

Population:1.4 billion
Official Language:Putonghua (Mandarin). Local dialects may be used
Hospital Records Language:Simplified Chinese
Electronic Hospital Records:Currently, paper records are used.

Twitter Facebook LinkedIn